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ABSTRACT
Objectives To estimate age- specific and sex- specific 
mortality risk among all SARS- CoV- 2 infections in four 
settings in India, a major lower- middle- income country and 
to compare age trends in mortality with similar estimates 
in high- income countries.
Design Cross- sectional study.
Setting India, multiple regions representing combined 
population >150 million.
Participants Aggregate infection counts were drawn 
from four large population- representative prevalence/
seroprevalence surveys. Data on corresponding number 
of deaths were drawn from official government reports of 
confirmed SARS- CoV- 2 deaths.
Primary and secondary outcome measures The 
primary outcome was age- specific and sex- specific 
infection fatality rate (IFR), estimated as the number of 
confirmed deaths per infection. The secondary outcome 
was the slope of the IFR- by- age function, representing 
increased risk associated with age.
Results Among males aged 50–89, measured IFR was 
0.12% in Karnataka (95% CI 0.09% to 0.15%), 0.42% in 
Tamil Nadu (95% CI 0.39% to 0.45%), 0.53% in Mumbai 
(95% CI 0.52% to 0.54%) and an imprecise 5.64% (95% 
CI 0% to 11.16%) among migrants returning to Bihar. 
Estimated IFR was approximately twice as high for males 
as for females, heterogeneous across contexts and rose 
less dramatically at older ages compared with similar 
studies in high- income countries.
Conclusions Estimated age- specific IFRs during the first 
wave varied substantially across India. While estimated 
IFRs in Mumbai, Karnataka and Tamil Nadu were 
considerably lower than comparable estimates from high- 
income countries, adjustment for under- reporting based 
on crude estimates of excess mortality puts them almost 
exactly equal with higher- income country benchmarks. In 
a marginalised migrant population, estimated IFRs were 
much higher than in other contexts around the world. 
Estimated IFRs suggest that the elderly in India are at an 
advantage relative to peers in high- income countries. Our 
findings suggest that the standard estimation approach 
may substantially underestimate IFR in low- income 
settings due to under- reporting of COVID- 19 deaths, and 
that COVID- 19 IFRs may be similar in low- income and 
high- income settings.
INTRODUCTION
Measuring the infection fatality rate (IFR) 
for SARS- CoV- 2 has been a major research 
objective since the beginning of the global 
pandemic. Reliable IFR estimates are essential 
for policy decisions on non- pharmaceutical 
interventions and vaccine allocation,1–3 and 
comparison of waves and variants. IFR esti-
mates almost universally rely on large- scale 
seroprevalence samples drawn from the 
general population, matched to official death 
data. Because of these data requirements, 
the vast majority of age- specific IFR estimates 
are based on data from high- income coun-
tries (HICs)2–6; meta- analyses estimating 
age- specific IFR in low- income and middle- 
income countries (LMICs)7 8 rely on untested 
assumptions that key epidemiological char-
acteristics (eg, transmission dynamics, age- 
specific death rate) in HICs are generalisable 
to low- income settings. Studies measuring IFR 
Strengths and limitations of this study
 ► This study provides representative estimates of the 
age- specific COVID- 19 infection fatality rate (IFR) in 
four socioeconomically diverse regions of India, a 
major lower- middle- income country, using the stan-
dard method for estimating IFR.
 ► Due to high measurement cost, there are very 
few age- specific IFR estimates in low- income and 
middle- income countries (LMICs), despite concerns 
that LMICs are more vulnerable and plausibly have 
different mortality patterns.
 ► This study uses the primary method of estimat-
ing IFR in settings around the world, combining 
population- representative prevalence/seropreva-
lence surveys with official death reports, allowing 
direct methodological comparison with dozens of 
similar estimates from high- income countries.
 ► We provide population- representative estimates for 
over 150 million people using the largest sample to 
date in an LMIC, and the first documentation of IFR 
among the large, highly vulnerable population of mi-
grant workers.
 ► The main limitation is our reliance on official reports 
of confirmed COVID- 19 deaths, which, due to under- 
reporting and undertesting, likely underestimate the 
true number of deaths.
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in LMICs mostly report age- aggregated IFR,9–13 which are 
difficult to compare across contexts; the age pattern of 
infection may vary and aggregate IFRs skew higher where 
older people contract a larger share of infections. Esti-
mates of age- specific IFR in LMICs have only been made 
from small or non- representative samples.14 15
Early modellers of lower- income settings warned that 
IFRs could be higher, due to worse baseline population 
health and under- resourced healthcare systems.8 15 16 
Other researchers observed low case fatality rates in sub- 
Saharan Africa and proposed that vaccination, infection 
history and effective mitigation strategies might have 
reduced mortality.17 18 The age pattern of deaths in lower- 
income countries has skewed younger than in HICs, more 
so than can be explained by age distribution alone.19–21
We calculated age- specific IFRs from four samples in 
India representing a combined population exceeding 
150 million. We used population- representative seroprev-
alence surveys in the city of Mumbai (N≅7000, popula-
tion 12.5 million) and in the states of Karnataka (N≅1200, 
population 61 million) and Tamil Nadu (N≅26 000, 
population 71 million). By matching these surveys to 
age- specific administrative death data, we calculated 
IFR without relying on non- representative testing data. 
Additionally we drew on a survey of COVID- 19 preva-
lence among randomly sampled short- term outmigrants 
(N≅4000 infections, population minimum 10 million), 
mostly working- age males, returning home to the state 
of Bihar with mortality follow- up. Because these migrants 
were randomly sampled and tracked until recovery or 
death, the death rate among those who tested positive is 
interpretable as an IFR.
Our objective was to calculate age- specific IFRs in four 
locations and compare them to international estimates, 
which are based mostly on HICs. We further examined 
heterogeneity of IFR within India and by age and sex.
Importantly, data collection took place during India’s 
first wave of COVID- 19 between March and December 
2020. India has since undergone a second, more severe 
wave between March and June 2021, characterised by 
much higher case counts, new and potentially more 
transmissible variants and a health system crisis.22 Excess 
mortality and reports suggest more severe infections and 
higher mortality in the second wave.22 Our IFR estimates 
apply to the first wave, and should not be interpreted as 
representative for the second.
METHODS
We studied three states and one megacity with disparate 
demographic and health characteristics (table 1). Qual-
itatively, Tamil Nadu and Karnataka are large, relatively 
wealthy, southern Indian states. Mumbai is India’s most 
populous city, and the capital of the western state Maha-
rashtra. Tamil Nadu, Karnataka and Maharashtra have 
relatively robust healthcare infrastructure and vital regis-
tration.23 In contrast, the northern state Bihar is one of 
the poorest in India, with the lowest stock of hospital beds 
per capita.24
The Bihar sample is limited to a subpopulation of 
returning migrants, primarily young male labourers who 
lost work opportunities during lockdown. The returning 
migrants to Bihar are part of a large population of internal 
labour migrants in India; a conservative estimate from 
the 2001 Census found that nearly 30 million workers 
migrated within India for employment.25 Tens of millions 
of migrants exited cities immediately after lockdown, 
including 6.3 million travelling on specially designated 
trains (‘Shramik Specials’) between May and August, 
2020.26 27 Short- term migrants were on average very poor 
even before the pandemic.28 India’s sudden lockdown left 
them unemployed, and many experienced extreme phys-
ical and economic duress on the long journey home.29 30
India began its first nationwide lockdown on 24 March 
2020, and by July 2021 had the second- highest number 
of country- wide confirmed COVID- 19 cases in the world. 
The Indian government spends roughly 1.5% of gross 
domestic product on healthcare, one of the world’s 
lowest rates.31 Discussion of India’s COVID- 19 prepared-
ness has focused on under- resourced public hospitals, a 




infections on July 31
Cumulative COVID- 19 
deaths on July 31






JHU CSSE COVID- 19 
data44
JHU CSSE COVID- 19 
data44 Kapoor et al24
Bihar 19.9 640 51 233 296 25.55
Maharashtra* 28.2 2802 411 798 14 994 172.94
Karnataka 27.4 3082 124 115 2314 391.62
Tamil Nadu 29.9 2831 245 859 3935 174.83
India 24.0 1964 1 695 988 36 511 137.62
Row 2 indicates the data source.
*Mumbai is the capital city of Maharashtra.
GDP, Gross domestic product; JHU CSSE, Johns Hopkins University Center for Systems Science and Engineering; NSDP, Net state domestic 
product.
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largely unregulated private healthcare sector and fear 
and stigma among the public surrounding infection.31
Data sources and study design
In Mumbai, Karnataka and Tamil Nadu, we matched 
representative seroprevalence surveys to administrative 
reports of confirmed COVID- 19 deaths.
In Mumbai, seroprevalence surveys were conducted 
for 2 weeks in July 2020 with representative sampling of 
three wards, one from each of the city’s three zones, strat-
ified by age, sex and slum/non- slum dwellers.10 Enumer-
ators sought voluntary consent to sample one member 
per household, rotating through age- gender groups. 
Thus, the sample composition is representative for city- 
wide age and sex, subject to consent rates. The sample 
consisted of 6904 participants (4202 from slums and 2702 
from non- slums), tested for IgG antibodies to the SARS- 
CoV- 2 N- protein using the Abbott Diagnostics Architect 
test. Data on cumulative deaths were collected from daily 
reports from the municipal governing body.
In Karnataka, seroprevalence surveys were conducted 
from 15 June 2020 to 29 August 2020, in representative 
samples of urban and rural areas in 20 out of 30 districts, 
stratified to generalise to 5 regions spanning all districts.32 
We can, therefore, take the ELISA positive test rate as 
an unbiased measure of region- level positivity rate. The 
sampling frame was not age stratified or sex stratified, and 
older individuals were oversampled relative to population 
age composition. We assume that ELISA positive test rate 
is representative by age–sex–region group, because there 
was no evidence that the age of the consenting member 
of each household was associated with seropositivity in 
the home. A total of 1196 participants were tested with an 
ELISA for antibodies to the receptor binding domain of 
the SARS- CoV- 2 virus, developed by Translational Health 
Science and Technology Institute in India. We collected 
district- level death data from the Government of Karna-
taka Department of Health and Family Welfare bulletins.
In Tamil Nadu, a representative seroprevalence 
survey was conducted between19 October 2020 and 30 
November 2020, of adults aged 18 and older, covering the 
state’s 37 districts.33 Collection times within districts were 
often significantly shorter. Enumerators divided districts 
into health unit districts, then randomly sampled urban 
and rural clusters. Within clusters, enumerators started 
at a randomly selected GPS starting point, sampling one 
person from households adjacent to the starting point 
(using the Kish method) to provide a biosample. Because 
household members were selected randomly, we similarly 
assume seropositivity is representative at the age–sex–
district level. Seropositivity was tested using either the 
iFlash- SARS- CoV- 2 IgG or the Vitros anti- SARS- CoV- 2 IgG 
CLIA kit. The analytical subsample was 26 107 antibody 
tests that could be conclusively determined as positive or 
negative. Case- level data on 12 019 recorded statewide 
COVID- 19 deaths, from March to December 2020 was 
collected from daily government reports.
In Bihar, the state government began COVID- 19 
testing among returning out- of- state migrants soon after 
the first positive case was identified in a migrant on 22 
March 2020. On 4 May, Bihar began to randomly select 
migrants for testing. Random testing continued until 21 
July, though for a brief window (22 May–31 May) only 
migrants returning from seven major cities were sampled. 
We isolated the subsample of randomly selected migrants, 
yielding 4362 individuals with positive tests.29 Tests were 
conducted with TrueNat machines manufactured by 
MolBio Diagnostics in Goa, with positive tests confirmed 
by real- time PCR kits.34 Bihar attempted to track all 
migrants who tested positive until they eventually recov-
ered or died.
In all locations, population data came from the 2012 
Socio- Economic and Caste Census.
Statistical analysis
In Mumbai, Karnataka and Tamil Nadu, we estimated 
infection counts from representative seroprevalence 
surveys. Methods for estimating infection counts are 
described in detail below. We matched infection counts 
to deaths assuming that the infection- seroconversion 
delay is on average 2 days shorter than the infection- death 
delay.35 36 To implement this, we calculated IFR as the 
cumulative number of deaths reported as of 2 days after 
the end of seroprevalence testing, divided by the number 
of infections. Testing sensitivity to this assumption, we 
replicate results using deaths from 1 and 2 weeks after 
last day of seroprevalence testing, effectively generating 
upper bounds for the number of deaths (online supple-
mental figures 1–3 in the online supplemental file 1). 
Where multiple evaluations of the antibody tests’ sensi-
tivity/specificity existed, we tested robustness to assuming 
minimum sensitivity (online supplemental figures 4 and 
5 in online supplemental file 1).
In Mumbai, we first adjusted for test sensitivity and spec-
ificity using the Rogan- Gladen correction,37 then calcu-
lated aggregate seroprevalence for each sampled ward 
and multiplied by ward population to estimate infection 
count. We estimated infection counts in non- sampled 
wards by assuming a constant rate of government under- 
reporting in wards in the same zone. This approach was 
supported by very similar case- to- seroprevalence ratios in 
the three wards with seroprevalence data (online supple-
mental table 1). Age- specific and sex- specific infection 
shares were based on the seroprevalence survey (online 
supplemental figure 6).
In Karnataka, we adjusted for test inaccuracies,37 
then used census population counts to aggregate from 
regional to state- level infection counts, reweighting 
to match regional age–sex distributions. Methods for 
matching dates and deaths to infections is described in 
detail in (online supplemental figure 7. Because the sero-
prevalence survey period in Bangalore spanned 2 months 
(compared with less than 3 weeks in the other regions), 
we show results excluding Bangalore, where deaths may 
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have been overestimated due to the longer survey period 
(online supplemental figure 8).
In Tamil Nadu, we first calculated the population- 
representative seropositivity rate by district–age–sex group 
and type of test kit, then adjusted for test inaccuracies. We 
estimated the number of statewide infections per district–
age–sex group by combining kit- specific seroprevalence 
estimates and multiplying by population, then summing 
across districts. In sensitivity checks, we re- estimated IFR 
limiting samples to districts where seroprevalence surveil-
lance lasted less than 3 weeks (online supplemental table 
2 and figure 9).
In Bihar, although enumerators attempted to track 
outcomes for all migrants, 1530 (35%) infected individ-
uals could not be tracked. In main estimates, we assumed 
that their fatality rates were the same as successfully 
tracked individuals; in sensitivity checks, we considered 
the possibility that all survived. High attrition is common 
in studies of migrant workers,29 with follow- up in this case 
complicated by the ongoing crisis. We limited our analytic 
sample to 3921 randomly sampled male migrants, for 
whom 2536 outcomes are known.
Information on underlying sample size, seroprevalence 
rate and number of deaths used to calculate IFRs in each 
location are in online supplemental tables 3–6 and online 
supplemental file 1.
Matching representative seroprevalence surveys to 
administrative death data is the primary method of IFR 
measurement everywhere in the world.2 4 5 In Bihar, 
because migrants were randomly sampled, there was no 
selection on symptomatic or severe cases, and mortality 
rates among positive cases can be interpreted as IFRs. 
As noted above, short- term migrants from Bihar are 
economically marginalised; their IFRs can be understood 
as representative for migrants, but not necessarily the 
general population.
We calculated IFRs in 10- year age bins, plus bins 10–49 
and 50–89, in all locations. We used two large- scale 
meta- analyses1 7 of age- specific SARS- CoV- 2 IFRs as refer-
ence groups. Both Levin et al1 and O’Driscoll et al7 draw 
almost exclusively from seroprevalence samples from 
Europe and the USA. The application of these samples 
to mortality in LMICs (as in O’Driscoll et al7) requires 
the as- yet untested assumption that multiple epidemio-
logical factors (eg, transmission dynamics) are uniform 
between HIC and LMIC. Levin et al1 do not report IFR 
by sex; we estimated sex- specific IFRs in Levin et al1 
by assuming the same sex ratio in IFR as reported in 
O’Driscoll et al7. For the larger age bins, we weighted 
age- specific IFR estimates from sample populations 
and meta- analyses by the Indian national population 
distribution, to ensure differences across contexts were 
driven by differences in age- specific IFRs, rather than 
population age distribution.
We calculated the slope of the natural log of IFR as a 
function of age by fitting a linear function to the most 
granular age- specific IFR data that could be obtained 
in each location. Additional details on the underlying 
samples and the methodology are in online supplemental 
materials. All analyses were conducted in Stata V.16.0.
Patient and public involvement
No patients were directly involved in this study. Patients 
would not be able to identify themselves in the data.
There was no direct data collection for this study; all data 
were gathered secondhand from public or published sources. 
The data used for measuring seroprevalence, COVID- 19 
deaths, and population were all anonymised and aggregated 
before we accessed it. We retrieved seroprevalence rate data 
in all locations from public sources, aggregated by age and 
sexi.10 29 33 38 Seroprevalence studies were designed and imple-
mented in partnership with local city and state governments. 
Details of patient involvement, protocols and institutional 
ethics approval for each seroprevalence study have been 
published in separate papers, and in reports from the respec-
tive governments.10 29 32 33
RESULTS
We plotted age- specific IFR for each location on a log scale, to 
enable comparison at all ages despite exponential increases 
at higher ages found in all countries (figure 1A,B). For both 
males and females, there is substantial variation in IFR across 
the four locations in India. In Karnataka, age- specific IFRs are 
10 times lower than those reported in the meta- analyses, and 
25 times lower over age 70. In Tamil Nadu, estimates were 
2–4 times lower than those in the meta- analyses. In Mumbai, 
estimates were close to the lower of the two meta- analyses 
at younger ages,7 but were considerably lower than meta- 
analyses after age 60. For 60–69 year- old men, for example, 
we measured an IFR of 0.17% (95% CI 0.092% to 0.240%) 
in Karnataka, 0.45% (95% CI 0.397% to 0.0.497%) in Tamil 
Nadu and 0.62% (95% CI 0.591% to 0.647%) in Mumbai 
(table 2); the two meta- analyses reported male IFR of 1.02%7 
and 1.86%1 in this age group.
In contrast, mortality among male migrants returning to 
Bihar was an order of magnitude higher. Mortality among 
males aged 60–69 was extremely high but measured impre-
cisely due to the small sample of older males (4.26%, 95% CI 
0.0% to 10.0%). The larger age bins allowed a more precise 
measure of IFR in Bihar (table 3). In both the 10–49 and 
50–89 age bins, mortality in Bihar was an order of magnitude 
higher than in the other Indian locations and at least twice as 
high as rates in meta- analyses, after weighting to the Indian 
age distribution to ensure cross- context comparability. For 
the 50–89 age group, estimates were not precise enough to 
rule out equality between Bihar and the other locations. For 
the 10–49 age group, we can rule out equality (p<0.01).
To the extent that an IFR advantage exists in India, it 
appears more strongly among the elderly. In most cases, 
i Details on public sources for seroprevalence data. Bihar migrant data may 
be requested from the Government of Bihar. Positive test rates by age, 
gender, ward, and slum in Mumbai can be found in the online supplement 
of.10 The same rates by district in Tamil Nadu can be found in the online 
supplement of.33 The same rates by region in Karnataka can be found in 
the supplement of.38
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the overall increase in IFR with age was considerably less 
steep than in the reference meta- analyses (figure 1), 
particularly at older ages. The meta- analyses suggest that 
an 80- year- old has about 100× the IFR of a 40- year- old; in 
Mumbai, the increase in risk factor is 40× and in Bihar it 
is only 10×. Specifically, male IFR increased on average 
by 4.7%, 9.6%, 10.3% and 11.6% with each year of age in 
Bihar, Mumbai, Karnataka and Tamil Nadu, respectively. 
We calculated comparable figures in the meta- analyses 
as 11.4%7 and 12.3%.1 Slopes for Indian females were 
uniformly flatter than those for the reference groups 
(figure 1B).
The main estimates are replicated in online supple-
mental materials under a range of different scenarios 
Figure 1 Age- specific infection fatality rate (IFR), comparing four locations in India with international estimates. Point 
estimates of age- specific IFR in (A) males and (B) females combining representative prevalence/seroprevalence studies and 
government- reported COVID- 19 deaths. IFRs were estimated for age bins 10–19 (Mumbai and Karnataka only), 20–29,…,60–69 
and 70+ in India. Slope of IFR age trends from the meta- analyses calculated by fitting a linear regression between age and 
natural log of IFR.
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and assumptions; the ordering of IFRs across regions 




Using best- practice methods applied in many HICs, 
we found substantial heterogeneity in age- specific 
COVID- 19 IFR in India. In all four locations, we found 
a weaker increase in IFR over age than seen in other 
countries.
In Mumbai, Karnataka and Tamil Nadu, estimated 
IFRs were considerably lower than those measured 
in richer countries. These results are qualified by the 
fact that COVID- 19 deaths are known to be under- 
reported in these locations, as we discuss below. In a 
tracked sample of male migrants returning to Bihar, 
IFR estimates were an order of magnitude higher than 
the other two locations and twice as high as the inter-
national reference groups.
Our Mumbai IFR estimates are representative for 
the city while Tamil Nadu and Karnataka estimates 
are representative for the state. IFR estimates for 
migrants returning to Bihar are plausibly generalis-
able to the tens of millions of migrant workers who 
exited cities, returning primarily to poorer rural areas, 
in the first months of the pandemic. Migrant workers 
differ from the general population, typically living in 
dense quarters that increase disease transmission,25 
with higher poverty rates,28 lower baseline health and 
higher prevalence of malaria, respiratory infections 
and acute febrile illness.25 In these aspects, our find-
ings on migrants have some generalisability to other 
extremely disadvantaged populations. However, the 
Figure 2 Age- specific infection fatality rates (IFRs) India: sensitivity checks. Main estimates and sensitivity checks of IFR of (A) 
males aged 10–49 years, (B) males aged 50–89, (C) females aged 10–49 and (D) females aged 50%–89%. 95% CIs shown in 
grey. In all locations, including meta- analyses, age- specific IFRs in smaller age bins have been weighted to India’s national age 
distribution, controlling for cross- location differences in population age. See online supplemental file 1 for details of sensitivity 
checks.
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actual journey migrants undertook is a unique risk 
factor. Overpacked trains likely heightened transmis-
sion and long travel distances, often on foot, increased 
physical vulnerability.27
Strengths and weaknesses of the study
The strength of this study was the use of seroprevalence 
data representing over 150 million people, with a suffi-
ciently large sample to calculate age- disaggregated IFR 
in a lower- middle- income country. The main weakness of 
the study is that, like all COVID- 19 population estimates, 
our results depend on the quality of underlying mortality 
data. The largest potential source of bias was our use of 
official reports of COVID- 19 deaths, which undercount 
the true number of deaths in all contexts.23 39
Though estimates of under- reporting are highly uncer-
tain, accounting for misreporting of deaths brings IFRs in 
three of the study locations close to estimates from HICs. 
Focusing on the 50–89 age group, in Mumbai, a doubling 
of COVID- 19 deaths is required to put estimated IFR in 
the range of the meta- analyses. It is plausible that deaths 
in Mumbai were undercounted by a factor of 2; between 
March and July, Mumbai recorded 6600 excess deaths in 
addition to the 6400 COVID- 19 deaths used in this study.39
In Karnataka and Tamil Nadu, COVID- 19 deaths 
would have to be under- reported by factors of 10 and 3 
respectively to bring IFR in line with international esti-
mates. Crude estimates from recently published data 
from India’s Civil Registration System suggest excess 
mortality rates during the first COVID- 19 wave were 
approximately six times higher than official COVID- 19 
deaths in both Karnataka and Tamil Nadu.40 If this 
ratio between excess mortality and reported COVID- 19 
deaths is an accurate measure of the death under- 
reporting rate, then this puts IFRs in Mumbai and Tamil 
Nadu close to the range of the HIC results, and Karna-
taka only slightly lower.
While these IFR estimates remain subject to bias, we 
note that we calculated IFR with the standard method-
ology used in many cross- national settings, many of which 
are also characterised by under- reporting of COVID- 19 
deaths. As described in the online supplemental file 1, 
wherever possible we made conservative choices that 
would bias our IFR estimates upward rather than down-
ward. In particular, antibodies may fade over time, so 
seroprevalence tests provide a lower bound on the cumu-
lative infection rate.41
Official misreporting of COVID- 19 deaths would not 
bias our IFR estimates in Bihar, due to the mortality 
follow- up methodology underlying these estimates. For 
our Bihar estimates to match the range of meta- analyses, 
deaths would need to have been overcounted by a factor 
of 2 for ages 50–89, and by 10 for ages 10–49. However, 
we do not know the base rate of migrant death. If migrant 
deaths would be high in absence of COVID- 19, due to 
migrants’ arduous return journeys, we may overstate the 
mortality attributable to COVID- 19 in this group.
Comparison with other studies
Few other studies have used sufficiently large seroprev-
alence samples to estimate age- specific IFR for a large 
lower- income population. Seroprevalence- based IFR 
estimates for older individuals in a Brazilian city14 were 
slightly lower than our estimate for Bihari migrants, and 
much higher than our seroprevalence- based estimates. 
However, seroprevalence samples of non- representative 
groups in sub- Saharan Africa implied high infection 
rates, suggesting either low overall mortality or substan-
tial under- reporting of deaths, consistent with our find-
ings in India.11 17 42
Studies have noted that the pattern of mortality in 
LMICs skews younger than would be predicted from the 
age distributions of death in HICs.19 21 Our study suggests 
that a flatter age profile in IFRs in lower- income settings 
could be a major factor driving this difference.
CONCLUSION AND FURTHER RESEARCH
In large samples representing India’s higher- income 
South, we found IFRs that broadly corresponded to those 
reported in richer countries, after adjusting for under-
counting. Among a sample of economically distressed 
migrants, we found IFRs that were twice as high, plausibly 
due to severe economic and physical distress. Migrant 
workers have worse health than the general population 
at baseline25 43; the circumstances at the beginning of the 
pandemic may have made this group exceptionally vulner-
able to adverse health events following viral infection.
At the time of writing, these estimates are among the 
best available in a lower- income setting. Improved surveil-
lance and accounting of SARS- CoV- 2 are critical invest-
ments that would improve our understanding of the 
fatality risk of the virus in lower- income settings. Further 
research is necessary to determine if IFRs are similar in 
high- income and low- income settings.
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We made use of data on all positive cases in the state of Bihar found during random testing of incoming migrants
during an early phase of the pandemic. The data was provided by the Health Department of the Government of
Bihar. The data contained a sample of 4,954 active infections and their outcomes, reported between March 22 (the
date on which the first positive case in Bihar was detected) and July 21, 2020. The vast majority of the sample
(over 99%) consisted of migrants travelling from within India into Bihar, most on designated trains. Migrants were
more likely to be sampled if they presented symptoms between March 22 and May 3. State policy beginning May
4 during the sample collection period mandated that travellers from within or outside India (mainly migrant workers
returning home due to travel restrictions) be randomly sampled and tested for COVID-19 infection from March
20 to May 22, and after May 31. Between May 22–31, only migrants from seven high-infection cities (National Capital
Region, Mumbai, Ahmedabad, Pune, Surat, Kolkata, and Bangalore) in India were randomly sampled. We isolated
the subsample of migrants who were randomly selected for testing, yielding 4,362 cases.
During the sample period, migrants were tested with TrueNat machines manufactured by MolBio Diagnostics
in Goa (India), and positive tests were confirmed with real-time reverse polymerase chain reaction (RT-PCR) kits
(CMO-PRC, 2020). Importantly, all infected migrants were tracked by the monitoring team, to determine whether they
eventually recovered or died. Among randomly sampled male migrants, 1,385 infected individuals (35%), whom we call
“lost”, could not be tracked and thus their final outcome is uncertain. The high level of attrition is common in studies of
migrant workers, whose frequent movement complicates administrative registration and tracking, particularly during a
crisis (Deshingkar et al., 2008). We considered several approaches to adjusting for attrition, described below. The migrant
sample, reflecting typical labor migration patterns in India, was overwhelmingly male (90%). Thus we limited our final
analytical sample to 3,921 randomly sampled male migrants, for 2,536 of whom outcomes (recovery or death) are known.
Estimating infection fatality rate
Because everyone in the sample had tested positive for SARS-CoV-2, IFRs were estimated as the share of deaths
among non-lost individuals in each age group. To account for potential biases due to attrition and delays between infec-
tion and recovery/death/reporting, we estimated IFRs using three separate methods, and report estimates from all three.
In age group a, denote the number of lost cases as na,lost, the number of recovered cases as na,recovered, and the
number of cases ending in death as na,died.
Method 1 (main estimation): In our main estimation, we assumed that lost cases had the same IFR as successfully
tracked cases, within each age group. This assumption was implemented by excluding lost individuals from the IFR




Method 2: In this estimation, we assumed that all lost cases eventually recovered. Thus Method 2 provided a




Method 3: The share of cases with successful followup declined in late July as the volume of migrants increased. In the
third method, to account for potential right-censoring of reported outcome rate due to delays between report of initial




| infection reported on or before July 7)
Standard errors were estimated with the normal approximation for a proportion from multiple draws from a
binomial distribution.
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Mumbai
Data
Data on seroprevalence were obtained from a representative, stratified, random sample of slum and non-slum
populations in three of twenty-four wards of Mumbai (see Malani et al. (2020) for full survey design). Sample collection
lasted two weeks and ended on July 14th in slums and July 19th in non-slums. The three wards were selected to
represent the city’s three broad zones (city, eastern suburbs, western suburbs); choice of sampled ward within each
zone was by convenience. The sample consists of 6,904 participants (4,202 from slums and 2,702 from non-slums), who
were tested for IgG antibodies to the SARS-CoV-2 N-protein using the Abbott Diagnostics ArchitectTM N-protein
based test. The samples were stratified by four age groups, sex, ward, and slum/non-slum residence.
Data on reported infections and deaths by ward and age distribution of deaths were provided in reports released
by the municipal governing body (Brihanmumbai Municipal Corporation, hereafter BMC). Data on ward population
in slums and non-slums came from the 2011 Population Census. Data on shares of population by age and sex in
each ward-slum came from the 2012 Socio-Economic and Caste Census.
Estimating IFR
Estimating number of infections. The seroprevalence survey reported seropositivity in four age groups (12–24,
25–39, 40–60, 61+), called “coarse bins”. To generate infection counts that could be compared with city death
statistics (which are reported in 10-year age bins), seropositivity by 10-year age bin was interpolated by fitting a
non-linear function over seropositivity in the coarse bins. For the main estimation, we interpolated seropositivity in
10-year bins, using the inverse distance-weighted mean of non-missing values (using the Stata package mipolate),
weighting with the squared inverse of distance. In each coarse bin, the median age of residents in Mumbai City was
used as the non-missing value for age. As a sensitivity analysis, we report IFR estimates using a piecewise cubic
Hermite (“pchip”) interpolation for seropositivity. Interpolation predicted seroprevalence for the midpoint of each
10-year age bin, separately by sex, ward, and slum status.
The estimated sensitivity of the chemiluminiscence immunoassay ranges from 90% (95% CI: 74 to 96) (USFDA, 2020)
to 96% (89 to 99) (Bryan et al., 2020) while specificity in those studies was 100% (95% CI: 95 to 100) and 99.0%,
respectively. We estimated seroprevalence from seropositivity using the Rogan-Gladen correction (Rogan and
Gladen, 1978) to account for imperfect accuracy of tests. In the main results, we used the midpoint of mean sensitivity
estimates (93.5%) and the midpoint of corresponding specificities (99%). As a sensitivity analysis, we replicated
results with an upper bound for seroprevalence based on the Abbott test’s lower bound of sensitivity (90%) and
upper bound of specificity (100%) (Bryan et al., 2020) (Figure 4).
Denote the estimated number of infections in age bin a, sex g in sampled ward s as:
înfags=SPags×popags
where SPag,s is the estimated seroprevalence rate, and popag,s is population.
Estimating the number of infections in non-sampled wards. BMC death data reported the ward of death, but
not the ward of residence. Discussion with government officials and review of the data indicated that the ward of
death was not a reliable indicator of ward of residence. This implied that calculating IFR by dividing the number of
ward-level deaths by the number of ward-level infections would overestimate deaths in wards with large hospitals and
underestimate them elsewhere. Instead, we used the seroprevalence surveys to generate estimates of city-wide infection
counts.
To estimate true number of infections in non-sampled wards, we drew on administrative ward-level infection counts
(which were universally available from city reports), and assumed that the BMC underestimated the true population
infection count at the same rate in sampled and non-sampled wards within the same zone. This assumption is supported
by Table 1, which shows that in the three wards where we obtained seroprevalence data, case multipliers were very similar.







The multiplier indicates the under-reporting rate in each zone z. The numerator of the expression is calculated
from the seroprevalence surveys as above, and the denominator is taken from the BMC reports. BMC-reported cases
were measured as of July 19, the last day of seroprevalence sample collection. We then multiplied the BMC’s reported
number of positive cases in non-sampled ward n in zone z by γz. That is,
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înfn,z=γz×BMC-reported casesn
The benefit of this approach is that it allows pandemic intensity to vary across wards, a realistic assumption given
significant ward-level variation in reported cases per capita and number of containment zones.
This approach also implicitly assumes that the BMC under-reports cases in slums and non-slums at the same
rate, i.e. a ward’s case multiplier does not depend on share of population living in slums. This assumption is also
supported by the consistent multipliers reported in Supplement Table 1, across three wards with different slum shares.
Estimating the number of infections in each age-sex group in non-sampled wards. We did not observe the age
and sex distribution of infections outside of the sampled wards, so it was necessary to assume that non-sampled wards
had the same age and sex distribution of infections of sample wards. This was supported by similar age and sex
distributions of infections in the three wards with seroprevalence surveys. Figure 9 shows the calculated age and sex
distribution of infections; note that the distribution of infections measured with seroprevalence skews younger than the
number of reported positive cases, which we presume omits many infected but asymptomatic young people. This
approach would cause error if the age distribution varied substantially across wards, but it is overall quite similar;
even the median age gap between slums and non-slums was less than one year.










where αag,s is the age-sex group’s share of total cases in sampled ward s.
Estimating the number of deaths. To map infection counts to death counts, we must make assumptions about the
delays between infection and death and between infection and seroprevalence. The literature suggests the distribution of
delay between symptom onset and death (Linton et al., 2020) that is wider than that between onset and seroconversion
(Stringhini et al., 2020). Linton et al. estimated a median time delay of 13 days (17 days with right truncation)
between illness onset to death. Stringhini et al. estimated a mean delay of 11. days between symptom onset and
seroconversion. Based on these estimates, we assumed that the delay between infection and death is on average two
days longer than the delay between infection and seroconversion. In the main results, the number of deaths was
therefore measured as the cumulative deaths reported in each Mumbai ward as of July 21. This is likely to slightly
overstate the IFR, since some deaths may have been associated with individuals who contracted the virus after testing
negative in the seroprevalence surveys. However, this upward bias is partially balanced out by the fact that the time
between seroconversion and death is not uniform and is likely to be longer than 2 days for a non-trivial share of cases.
Rather than model non-uniform delays between infection and death, we bounded our IFR estimates from above
by choosing more conservative death dates. In sensitivity analyses reported below (Figure 1), we replicated IFR
estimates using deaths from one week (July 28) and two weeks (August 4) after the end of seroprevalence surveying,
both of which plausibly overestimated the number of deaths related to the seroprevalence surveys, given the context
of steadily increasing case counts in Mumbai from June to August.
The assumption that deaths measured 1 and 2 weeks later will lead to upward biased IFRs is further strengthened
by recent evidence from roughly 125,000 cases in two other Indian states (Laxminarayan et al., 2020), which found
that delays between case report and death were significantly shorter than delays found in China and the United
States (Lewnard et al., 2020).
We used the age distribution of deaths as reported by the BMC up to the date used for measuring deaths, and
the sex distribution (65% male, 35% female) up to August 3 (Debroy, 2020) (the sex distribution of deaths was not
included in earlier reports). This yields the estimated number of city-wide deaths by age-sex group, dag.







Standard errors of IFRs were calculated reflecting propagation of the design-based standard errors of the age- and
sex-specific seroprevalence estimates with a normal approximation.
Karnataka
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Data
Data on seroprevalence were obtained from the Karnataka Seroprevalence Survey (hereafter KSS) a state-wide
representative sample of urban and rural areas in 20 out of 30 districts in Karnataka, representing 5 broader regions
(see Mohanan et al. (2021) for a detailed survey description). The sample was collected from June 15 to August
29, 2020. Collection times within individual regions were significantly shorter. The study sample was drawn from an
existing representative sample of a panel survey—the Consumer Pyramids Household Survey (CPHS)—collected by the
Center for Monitoring Indian Economy (CMIE). Our analytical subsample consists of 1,196 tests for IgG antibodies to
the receptor binding domain (RBD) of the SARS-CoV-2 virus using an ELISA test developed by Translational Health
Science and Technology Institute, India. The sample was not stratified by age and sex, an issue addressed below.
Data on confirmed COVID-19 deaths by district were drawn from Government of Karnataka Department of
Health and Family Welfare bulletins, which are released several times per week. Data on the age distribution of total
COVID-19 deaths were given by public reports from the state COVID-19 task force. Data on the sex distribution
of deaths by age group were obtained from an individual-level dataset of confirmed COVID-19 deaths which was
updated through July. The case-level death data were parsed from covid19india.org. Age- and sex-disaggregated
population for districts and regions was drawn from the 2012 Socio-Economic and Caste Census (SECC).
Estimating IFR
Estimating the number of infections. The KSS dataset was designed to be representative of 5 broader regions in
Karnataka. We therefore can take the ELISA positive test rate as an unbiased measure of the region-level positivity
rate. We pooled the data across regions to obtain a statewide test positivity rate in each age and sex group, weighting
by region population in each age-sex group.
We then corrected for the sensitivity (84%) and specificity (100%) of the ELISA imunoassay (Chaudhuri et al., 2020),
using the Rogan-Gladen correction (Rogan and Gladen, 1978). This yielded the estimated seroprevalence by age-sex
group SPag, which is multiplied by population popag in each age-sex bin to generate an estimated number of infections
înfag, as was done in Mumbai.
Estimating the number of deaths. The seroprevalence samples were collected at different times in different regions,
with the survey period spanning roughly two months (Table 2). To estimate an IFR, we need to match the timing
of deaths to the timing of seroprevalence surveying in each region.
Choice of dates for measuring deaths. As in Mumbai, we worked from an assumption that the average time
difference between seroconversion and death was two days, while testing sensitivity to alternate assumptions (Figure 2).
We therefore matched the estimated number of infections calculated in each region to the number of deaths recorded
in administrative data two days after the last date of seroprevalence surveying. As in Mumbai, if the two-day delay
between seroconversion and death was uniform, this approach would overestimate the IFR, because it counts the
deaths of some people who may have been infected after recording negative seroprevalence tests.
In all regions except Bangalore, seroprevalence surveying was conducted over a three week period or less, making it
straightforward to match test data to death data. In Bangalore, surveying was begun in mid-June but was interrupted
by a lockdown. Survey teams returned to finish sampling in the last week of August. Matching Bangalore deaths to
the last date of seroprevalence surveying is therefore likely to overestimate the IFR, because a number of those deaths
may have been associated with individuals contracting SARS-CoV-2 after testing negative. It was not possible to
disaggregate the early and late surveys because death reporting was at the district level, and the early and late survey
groups were not representative in and of themselves. To adjust for increased uncertainty regarding the number of
infections in Bangalore, we therefore report a sensitivity analysis for all of Karnataka excluding Bangalore (Figure 5).
On some days, official deaths were not reported; in those cases, we used deaths from the following day.1
Estimating the number of deaths in each demographic group: The Karnataka state government released total
death counts on a daily basis, but only intermittently published the age distribution of state-wide deaths. To attribute
daily deaths to age and sex groups, we used the age distribution of deaths from the nearest available date. The
longest period between the date used for deaths and the date used for age-shares was 13 days.
Government reports provided age shares of deaths in 10-year bins in the form (e.g.) 51-60, while the seroprevalence
surveys provided age bins in the form (e.g.) 50-59. To harmonize the age groups, we use the medians of the provided
bins (e.g. median of 51-60 is 55.) to interpolate death data to match the age bins in the seroprevalence data, using
an inverse distance weighted average method via the mipolate Stata package. Because the target age bins were very
close to the available age bins, the risk of error here is small. As a sensitivity test, we replicated IFRs using piecewise
cubic Hermite interpolation. For more details, see the discussion on interpolation in Mumbai.
1In Belgaum, the target date was July 27th; we used July 28. In the sensitivity test, the target date was August 10; we used August 11.
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In the absence of death data disaggregated by age and sex on most dates, we assumed that, within age group, the
sex distribution of deaths was uniform across regions and equal to the state-wide sex distribution of deaths reported
between April and July. This assumption is supported by the finding that IFRs among males were approximately
double those among females, consistent with reports from other countries.
Standard errors of IFRs reflect propagation of design-based standard errors of the age- and sex-specific seroprevalence
estimates with a normal approximation.
Tamil Nadu
Data
Data on seroprevalence in Tamil Nadu comes from a state-conducted population-level seroprevalence survey of
26,640 adults aged 18 and older, covering the 37 districts of the state. The sample was collected between October
19 and November 30, 2020. Collection times within districts were often significantly shorter. The sampling frame
divided Tamil Nadu’s 37 administrative districts (as of February 2020) into health unit districts (HUDs), then formed
and randomly sampled urban and rural clusters. Within clusters, enumerators started at a randomly selected GPS
starting point, sampling one person from households adjacent to the starting point (using the Kish method) to provide
a biosample, until 30 persons were sampled per cluster. Serum was analyzed for IgG antibodies to the SARS-CoV-2
spike protein using either the iFlash-SARS-CoV-2 IgG (Shenzhen YHLO Biotech; sensitivity of 95% and specificity
of 95% per manufacturer (Shenzhen YHLO Biotech No. Ltd., 2020)) or the Vitros anti-SARS-CoV-2 IgG CLIA
kit (Ortho- Clinical Diagnostics; sensitivity of 90% and specificity of 100% per manufacturer). For uniformity, in each
district, one type of kit was used; in one district (Chennai) both kits were used. Our analytical subsample consists
of 26,107 CLIA antibody tests that could be conclusively determined as positive or negative.
Case-level data on state-wide COVID-19 deaths was collected from daily government reports released on
https://stopcorona.tn.gov.in/daily-bulletin/. The data cover all recorded deaths, beginning on March 25
and updated until December 24, 2020. The data was collected and shared by the faculty and staff of the Urban
Expansion Observatory at Pillai College, New Panvel, Maharashtra. The dataset contains 12,019 observations, each
with information about age, sex, dates of reported positive test and death, and district. Age- and sex-disaggregated
population data were from the 2012 Socio-Economic and Caste Census.
Estimating IFR
Estimating the number of infections. We estimated the number of state-wide infections associated with measured
seroprevalence in three steps. First, we calculated positive test rate by district-age-sex group, separately for each
kit. Positive test rate was estimated by regressing an indicator for positive result on district-age-sex group indicators,
clustering standard errors within the randomly sampled clusters. Seroprevalence sample collection was stratified
by district, health unit district (HUD), then cluster; within clusters, age and sex of test participants was random.
Thus we take the positive test rate for each district-age-sex group as representative.
Second, we adjusted for test inaccuracies for each kit, using the Rogan-Gladen correction (Rogan and Gladen, 1978)
and the manufacturer-provided sensitivity and specificity. In a sensitivity check, we utilized the lowest estimated
sensitivity and corresponding specificity, from any manufacturer-conducted or independent analyses of each kit (Figure
7). Independent analysis of the iFlash kit from Shenzhen YHLO Biotech estimated sensitivity of 93% (95% CI: 84
to 97) and specificity of 92% (85 to 97) (Plebani et al., 2020). FDA evaluation of the Vitros kit from Ortho-Clinical
Diagnostics suggests 100% sensitivity (95% CI: 88 to 100) and 100% specificity (95 to 100) (USFDA, 2020), while
other analysis estimated a sensitivity of 98% (92 to 100) and specificity of 97% (85 to 100) (Theel et al., 2020). Note
that, unlike in Mumbai and Karnataka, the minimum sensitivity of the kits in Tamil Nadu had lower corresponding
specificity, leading to lower overall seroprevalence estimates. In the district in which both kits were used, kit-specific
seroprevalence estimates were averaged, using proportion of sample size (by age-sex group) as the weight.
Third, we estimated number of infections in each district-age-sex group by multiplying seroprevalence rate by
population. Age- and sex-disaggregated population data was available for census districts. Finally, estimated state-wide
infections by age-sex group were calculated by simply summing over all districts.
Estimating number of deaths in each demographic group. As in Mumbai and Karnataka, we matched the esti-
mated number of infections calculated in each district to the number of deaths recorded in administrative data two days
after the last date of seroprevalence surveying. We test sensitivity to alternative assumptions by measuring cumulative
deaths 1 week and 2 weeks after the main date (Figure 3). As explained in the supplement sections on Mumbai and Kar-
nataka, these are all plausible over-estimates of deaths associated with the measured seroprevalence level. Cumulative
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deaths in each demographic group were measured up to the specified date. Cumulative deaths were measured fromMarch
through December, a longer span than in other locations. This may over-estimate deaths, and therefore over-estimate
IFR, if infected individuals gradually become seronegative after recovery. Available evidence suggests that antibody loss
varies significantly with symptom severity ((Ripperger et al., 2020; Ibarrondo et al., 2020; Long et al., 2020)). Because
we cannot precisely estimate antibody loss rates across the population, and because IFR estimates in Tamil Nadu are
the lowest across the four locations, we simply note that, given available data, our IFR estimates are conservatively high.
Seroprevalence surveying lasted longer than three weeks in 6 out of 37 districts. In these districts, there is a risk that
seroprevalence in the population changed during sample collection. During a period of increasing pandemic intensity, this
may under-estimate seroprevalence, over-estimating IFR. As a sensitivity check, we limit analysis of both seroprevalence
and deaths to the 31 districts in which seroprevalence sample collection was less than three weeks (Figure 8).
Age- and sex-specific IFRs were estimated as the proportion of state-wide deaths divided by estimated infections.
Standard errors reflect propagation of error from the HUD-age-sex estimates of positive test rates.
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eFigure 1
Mumbai: sensitivity
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“Date of death” refers to the day on which we measured cumulative deaths as reported by the city government (BMC). The main date
specification measured deaths two days after the end of seroprevalence sample collection. Graphs by sex with 95% confidence intervals.
Standard errors reflect propagation of error from design-based uncertainty of seroprevalence estimates. IFRs are calculated in age bins 0-19,
20-29, ... 60-69, and 70+.
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eFigure 2
Karnataka: sensitivity
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“Date of death” refers to the date on which we measured cumulative COVID-19 deaths. Main date of specification was determined
separately for each sampled region as two days after the median date of sample collection. Graphs by sex with 95% confidence intervals.
Standard errors reflect propagation of error from design-based uncertainty of seroprevalence estimates. IFRs are calculated in age bins 0-9,
... 60-69, and 70+.
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eFigure 3
Tamil Nadu: sensitivity
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“Date of death” refers to the date on which we measured cumulative COVID-19 deaths. Main date of specification was determined
separately for each sampled district (N = 37) as two days after the last date of sample collection. Graphs by sex with 95% confidence
intervals. Standard errors reflect propagation of error from uncertainty in estimating positive test rate by HUD-age-sex group. IFRs are
calculated in age bins 18-29, 30-39 ... 60-69, and 70+.
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eFigure 4
Mumbai:
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“Main seroprevalence estimates” use midpoint sensitivity estimate of the Abbott antibody test to calculate seroprevalence from
seropositivity in sampled wards, then interpolates seroprevalence to finer age bins with inverse distance weighting (IDW). “High
seroprevalence estimates” use minimum sensitivity of the Abbott test to calculate seroprevalence from seropositivity and IDW interpolation.
The final sensitivity analysis uses midpoint sensitivity, but piecewise cubic Hermite interpolation to estimate seroprevalence in finer bins.
Graphs by sex with 95% confidence intervals. Standard errors reflect propagation of error from design-based uncertainty of seroprevalence
estimates. IFRs are calculated in age bins 0-19, 20-29, ... 60-69, and 70+.
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eFigure 5
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IFRs in main specification are calculated by pooling seroprevalence and death estimates from all five sampled regions of Karnataka.
IFRs excluding Bangalore pool from the four remaining regions. Graphs by sex with 95% confidence intervals. Standard errors reflect
propagation of error from design-based uncertainty of seroprevalence estimates. Confidence intervals are not reported for Bangalore due to
small sample size, and age-specific estimated IFRs in Bangalore should not be interpreted as conclusive. IFRs are calculated in age bins
0-9, ... 60-69, and 70+.
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eFigure 6
Karnataka:
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Government reports provide age-shares of deaths in age bins of the form 11-20, 21-30, etc. To match seroprevalence estimates, we
interpolate age-shares of deaths in the form 10-19, 20-29, etc. Main specification uses the inverse distance weighted average (IDW) to
interpolate age shares. sensitivity analysis uses piecewise cubic Hermite interpolation. Interpolation was done with Stata package mipolate.
Graphs by sex with 95% confidence intervals. Standard errors reflect propagation of error from design-based uncertainty of seroprevalence
estimates. Confidence intervals are not reported for Bangalore due to small sample size, and age-specific estimated IFRs in Bangalore
should not be interpreted as conclusive. IFRs are calculated in age bins 0-9, ... 60-69, and 70+.
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eFigure 7
Tamil
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Two kits were used to evaluate seropositivity. Seroprevalence rate was calculated from the seropositivity rate using the Rogan-Gladen
correction for imperfect test sensitivity and specificity. Main estimation used the manufacturer-provided sensitivity and corresponding
specificity of the kits. The robustness check uses the lowest estimated sensitivity of both kits, which was the manufacturer-provided
estimate for the Ortho-Clinical kit. Graphs by sex with 95% confidence intervals. Standard errors reflect propagation of error from
uncertainty in estimating positive test rate by HUD-age-sex group. IFRs are calculated in age bins 18-29, 30-39 ... 60-69, and 70+.
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eFigure 8
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IFRs in main specification are calculated by pooling seroprevalence and death estimates from all 37 districts of Tamil Nadu. IFRs
estimated from districts with shorter collection time exclude 6 districts where seroprevalence surveying lasted longer than three weeks.
Graphs by sex with 95% confidence intervals. Standard errors reflect propagation of error from uncertainty in estimating positive test rate
by HUD-age-sex group. IFRs are calculated in age bins 18-29, 30-39 ... 60-69, and 70+.
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eFigure 9
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“Total positive cases” refers to the estimated number of total infections in Mumbai, multiplying age- and sex-specific seroprevalence rate
by group population, summed across age-sex groups and wards. The age- and sex-share of total cases refers to estimated number of
infections in age-sex group ag, divided by estimated total infections. Age bins are 0-19, 20-29, ...60-69, and 70+.
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1 Supplementary Tables
eTable 1
Zone-wise case multipliers for main and higher seroprevalence estimates based on sampled wards
No. infections γz
Ward Zone BMC report main SP high SP main SP high SP
(1) (2) (3) (4) (5) (6) (7)
F North City 4,017 190,652 211,835 47.6 52.3
M West Eastern 2,965 139,791 155,322 47.5 52.9
R North Western 2,421 145,413 161,569 60.6 66.4
“Number of infections, main SP” refers to the estimated seroprevalence ( using the midpoint estimated sensitivity of the antibody test)
multiplied by population in each sampled ward. “Number of infections, high SP” uses lowest bound sensitivity of the antibody test. Case
multiplier “γz, main SP” (Column 6) was calculated by dividing Column 4 by Column 3. “γz, high SP” (Column 7) was calculated by
dividing Column 5 by Column 3. Main SP indicates seroprevalence estimated from midpoint of two published estimates of sensitivity of
the antibody test. High SP indicates seroprevalence was estimated using the minimum sensitivity and maximum specificity of the antibody
test, generating a upper-bound estimate.
eTable 2
Karnataka: duration of sample collection by region
Region Duration of sample collection (days) Dates of sample collection
Bangalore 73 June 17 – August 29
Mysore 18 August 3 – August 21
Kannada 16 August 6 – August 21
Belgaum 17 July 8 – July 25
Gulbarga 10 July 21 – July 31
eTable 3
Mumbai: summary statistics used in calculating IFR
Seroprev. sample size Seroprev. rate No. deaths
Age Male Female Male Female Male Female
(1) (2) (3) (4) (5) (6) (7)
10–19 210 166 0.339 0.573 14 7
20–29 642 561 0.323 0.555 59 32
30–39 946 897 0.344 0.476 168 90
40–49 929 811 0.428 0.502 454 245
50–59 750 605 0.403 0.531 983 530
60–69 424 307 0.441 0.494 1094 589
70–89 153 88 0.503 0.397 1000 539
Columns 2 and 3 are the number of participants in the seroprevalence survey. Columns 4 and 5 reflect the city-wide seroprevalence rate,
adjusted for antibody test sensitivity and specificity. Because we allowed seroprevalence rate to vary across wards, seroprevalence was
calculated as number of estimated infections divided by population. Columns 6 and 7 are the number of deaths reported by the city
government, split by gender with the assumption that deaths were 65% male, 35% female. See Materials and Methods for details.
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eTable 4
Karnataka: summary statistics used in calculating IFR
Seroprev. sample size Seroprev. rate No. deaths
Age Male Female Male Female Male Female
(1) (2) (3) (4) (5) (6) (7)
10–19 28 30 0.503 0.430 5 14
20–29 84 86 0.342 0.539 59 41
30–39 84 137 0.443 0.388 191 85
40–49 178 175 0.533 0.516 406 168
50–59 129 127 0.516 0.513 687 359
60–69 59 41 0.367 0.474 801 326
70–89 19 19 0.468 0.485 549 321
Columns 2 and 3 are the number of participants in the seroprevalence survey. Columns 4 and 5 reflect the state-wide seroprevalence
rate, adjusted for antibody test sensitivity and specificity. Columns 6 and 7 are the number of deaths reported by the state government.
See Materials and Methods for details.
eTable 5
Tamil Nadu: summary statistics used in calculating IFR
Seroprev. sample size Seroprev. rate No. deaths
Age Male Female Male Female Male Female
(1) (2) (3) (4) (5) (6) (7)
18–29 2267 3025 0.292 0.242 56 41
30–39 1794 3576 0.268 0.306 184 90
40–49 1719 3041 0.276 0.295 629 259
50–59 1475 2340 0.284 0.296 1619 614
60–69 1229 1488 0.261 0.249 2510 923
70–89 742 659 0.232 0.258 3029 882
Columns 2 and 3 are the number of participants in the seroprevalence survey. Columns 4 and 5 reflect the state-wide seroprevalence
rate, adjusted for antibody test sensitivity and specificity. Because we calculated seroprevalence and corresponding deaths using different
dates for different districts, seroprevalence was calculated as total infections across district at time of seroprevalence data collection, divided
by population. Columns 6 and 7 are the number of deaths reported by the state government, summed across districts at the time of
seroprevalence data collection. See Materials and Methods for details.
eTable 6
Bihar male migrants: summary statistics used in calculating IFR
Age No. infected % successfully tracked No. deaths
(1) (2) (3) (4)
10–19 568 0.674 0
20–29 1472 0.628 6
30–39 989 0.670 12
40–49 543 0.602 5
50–59 189 0.667 3
60–69 69 0.681 2
70–89 13 0.615 1
The table summarizes the group used for analysis: randomly sampled male migrants. Column 2 is the number of men in the sample,
who were all infected. Column 3 is the percentage of infected men for whom trackers successfully confirmed an outcome: either recovery or
death. Column 4 is the number of confirmed deaths.
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